Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
As we count down the remaining days until the launch of this global event in Kraków, Poland, ADI is proud to share a message from our CEO, Paola Barbarino, and highlight some of our key speakers joining us from 24-26 April 2024.
ADI is pleased to welcome both Her Majesty The Queen Sofía of Spain and Her Royal Highness Princess Muna Al Hussein of Jordan to ADI’s 36th International Conference
The Centers for Medicare & Medicaid Services (CMS) in the US confirms requirement for clinical trials to access Aduhelm but broadens which trials are eligible.
The study by Institute for Health Metrics and Evaluation (IHME) published in The Lancet predicts 153 million people will be living with Alzheimer’s disease by 2050.
This follows the result of the negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting in November.
As 2021 comes to an end, ADI CEO Paola Barbarino reflects on the work of ADI in 2021 and what we are looking towards to in 2022.
To date, only 37 of 194 countries that signed up to implement the WHO Global action plan on dementia have created and funded national dementia plans. Our new campaign aims to galvanise and encourage more governments to develop national dementia plans following their 2017 commitment.
The news follows a negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting.
Eisai’s lecanemab will represent the second anti-Amyloid Beta therapy to be evaluated by the FDA as a disease modifying treatment for early Alzheimer’s disease.
This report reviews progress towards the implementation of the 7 action areas of the plan by Member States, WHO and civil society, and all those involved in tackling the dementia pandemic.